BRST5:Phyllodes tumour - Revision history

Kgeiersbach at 20:56, 2 October 2025

2025-10-02T20:56:54Z

← Older revision		Revision as of 15:56, 2 October 2025
Line 5:		Line 5:
	{{Under Construction}}		{{Under Construction}}

	<span style="color:#0070C0">(''General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)''</span>		<br />
	==Primary Author(s)*==		==Primary Author(s)*==
	Emilie Lalonde, PhD, London Health Sciences Center and Western University, London, Ontario, Canada		Emilie Lalonde, PhD, London Health Sciences Center and Western University, London, Ontario, Canada

Bailey.Glen at 17:50, 3 July 2025

2025-07-03T17:50:56Z

← Older revision		Revision as of 12:50, 3 July 2025
Line 35:		Line 35:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~


	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 22:11, 25 May 2025

2025-05-25T22:11:15Z

← Older revision		Revision as of 17:11, 25 May 2025
Line 98:		Line 98:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|1		\|1
Line 175:		Line 175:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|		\|
Line 194:		Line 194:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|''FLNA''		\|''FLNA''

Bailey.Glen at 20:34, 25 May 2025

2025-05-25T20:34:25Z

← Older revision		Revision as of 15:34, 25 May 2025
Line 53:		Line 53:
	==Related Terminology==		==Related Terminology==


	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Cystosarcoma phyllodes
	\|}		\|}

Bailey.Glen: Repeat columns removed

2025-03-27T14:17:39Z

Repeat columns removed

Show changes

Bailey.Glen at 14:16, 27 March 2025

2025-03-27T14:16:08Z

← Older revision		Revision as of 09:16, 27 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Phyllodes tumour}}		{{DISPLAYTITLE:Phyllodes tumour}}[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]
	[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]

	{{Under Construction}}		{{Under Construction}}

Bailey.Glen at 18:11, 24 March 2025

2025-03-24T18:11:16Z

Show changes

Kgeiersbach: /* Individual Region Genomic Gain/Loss/LOH */

2025-01-09T04:14:36Z

Individual Region Genomic Gain/Loss/LOH

← Older revision		Revision as of 23:14, 8 January 2025
Line 197:		Line 197:
	\|D		\|D
	\|		\|
	\|No significant difference between benign, borderline, and malignant tumors. Frequently co-mutated with ''RARA'', ''TERT'' promoter, ''SETD2'', ''EGFR''.<ref>{{Cite journal\|last=Cani\|first=Andi K.\|last2=Hovelson\|first2=Daniel H.\|last3=McDaniel\|first3=Andrew S.\|last4=Sadis\|first4=Seth\|last5=Haller\|first5=Michaela J.\|last6=Yadati\|first6=Venkata\|last7=Amin\|first7=Anmol M.\|last8=Bratley\|first8=Jarred\|last9=Bandla\|first9=Santhoshi\|date=2015-04\|title=Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors\|url=https://pubmed.ncbi.nlm.nih.gov/25593300\|journal=Molecular cancer research: MCR\|volume=13\|issue=4\|pages=613–619\|doi=10.1158/1541-7786.MCR-14-0578\|issn=1557-3125\|pmc=4936398\|pmid=25593300}}</ref><ref name=":5" /><ref name=":4" />		\|No significant difference between benign, borderline, and malignant tumors. Frequently co-mutated with ''RARA'', ''TERT'' promoter, ''SETD2'', ''EGFR''.<ref>{{Cite journal\|last=Cani\|first=Andi K.\|last2=Hovelson\|first2=Daniel H.\|last3=McDaniel\|first3=Andrew S.\|last4=Sadis\|first4=Seth\|last5=Haller\|first5=Michaela J.\|last6=Yadati\|first6=Venkata\|last7=Amin\|first7=Anmol M.\|last8=Bratley\|first8=Jarred\|last9=Bandla\|first9=Santhoshi\|date=2015-04\|title=Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors\|url=https://pubmed.ncbi.nlm.nih.gov/25593300\|journal=Molecular cancer research: MCR\|volume=13\|issue=4\|pages=613–619\|doi=10.1158/1541-7786.MCR-14-0578\|issn=1557-3125\|pmc=4936398\|pmid=25593300}}</ref><ref name=":5" /><ref name=":4" /> ''MED12'' is also frequently mutated in fibroadenoma, a related fibroepthelial tumor.<ref name=":5" />
	\|-		\|-
	\|''RARA''		\|''RARA''
Line 320:		Line 320:
	<br />		<br />
	==References==		==References==
	(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span>		<br /><references />

	<br />
	<references />

Kgeiersbach: /* Gene Mutations (SNV/INDEL) */

2025-01-09T04:10:07Z

Gene Mutations (SNV/INDEL)

@@ Line 214: / Line 214: @@
+|
 |No significant difference between benign, borderline, and malignant tumors. Frequently co-mutated with ''MED12''.<ref name=":4" /><ref name=":6" />
 |-
 |''EGFR''
@@ Line 272: / Line 280: @@
+|
 |More common in malignant tumors.<ref name=":4" /> Germline mutations have been associated with phyllodes tumors.<ref>{{Cite journal|last=Rosenberger|first=Laura H.|last2=Thomas|first2=Samantha M.|last3=Nimbkar|first3=Suniti N.|last4=Hieken|first4=Tina J.|last5=Ludwig|first5=Kandice K.|last6=Jacobs|first6=Lisa K.|last7=Miller|first7=Megan E.|last8=Gallagher|first8=Kristalyn K.|last9=Wong|first9=Jasmine|date=2020-10|title=Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing|url=https://pubmed.ncbi.nlm.nih.gov/32504368|journal=Annals of Surgical Oncology|volume=27|issue=10|pages=3633–3640|doi=10.1245/s10434-020-08480-z|issn=1534-4681|pmc=9945652|pmid=32504368}}</ref>
 |}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
 ==Epigenomic Alterations==
@@ Line 323: / Line 323: @@
 <br />

Kgeiersbach at 04:08, 9 January 2025

2025-01-09T04:08:15Z

Show changes